XML 23 R13.htm IDEA: XBRL DOCUMENT
v3.22.4

SEGMENT INFORMATION | 3 Months Ended
--- | ---
Dec. 31, 2022
SEGMENT INFORMATION |
SEGMENT INFORMATION | NOTE G – SEGMENT INFORMATION As detailed in Note B above, the Company has three reportable segments; (1) Therapeutic DNA Production Services, (2) MDx Testing Services, and (3) DNA Tagging and Security Products and Services. Resources are allocated by our CEO, COO CFO and CLO whom, collectively the Company has determined to be our CODM. Information regarding operations by segment for the three-month period ended December 31, 2022 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | 127,506 | ​ | $ | — | ​ | $ | 388,890 | ​ | $ | 516,396
Service revenues | ​ |  | 121,743 | ​ |  | — | ​ |  | 110,318 | ​ |  | 232,061
Clinical laboratory service revenues | ​ |  | — | ​ |  | 4,565,815 | ​ |  | — | ​ |  | 4,565,815
Less intersegment revenues | ​ |  | — | ​ |  | (51,520) | ​ |  | — | ​ |  | (51,520)
Total revenues | ​ | $ | 249,249 | ​ | $ | 4,514,295 | ​ | $ | 499,208 | ​ | $ | 5,262,752
Gross profit | ​ | $ | 170,924 | ​ | $ | 1,933,219 | ​ | $ | 273,540 | ​ | $ | 2,377,683
(Loss) income from segment operations (a) | ​ | $ | (852,253) | ​ | $ | 1,109,884 | ​ | $ | (474,715) | ​ | $ | (217,084)
​ NOTE G – SEGMENT INFORMATION, continued Information regarding operations by segment for the three-month period ended December 31, 2021 is as follows:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Therapeutic DNA | ​ | MDx Testing | ​ | DNA Tagging and | ​ |  | ​
​ |  | Production |  | Services |  | Security Products |  | Consolidated
Revenues: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Product revenues | ​ | $ | — | ​ | $ | 342,821 | ​ | $ | 483,490 | ​ | $ | 826,311
Service revenues | ​ |  | 89,438 | ​ |  | — | ​ |  | 49,835 | ​ |  | 139,273
Clinical laboratory service revenues | ​ |  | — | ​ |  | 3,349,658 | ​ |  | — | ​ |  | 3,349,658
Less intersegment revenues | ​ |  | — | ​ |  | (149,536) | ​ |  | — | ​ |  | (149,536)
Total revenues | ​ | $ | 89,438 | ​ | $ | 3,542,943 | ​ | $ | 533,325 | ​ | $ | 4,165,706
Gross profit | ​ | $ | 89,438 | ​ | $ | 820,690 | ​ | $ | 199,010 | ​ | $ | 1,109,138
(Loss) income from segment operations (a) | ​ | $ | (924,778) | ​ | $ | (334,988) | ​ | $ | (896,399) | ​ | $ | (2,156,165)
​ Reconciliation of segment loss from operations to consolidated loss before provision for income taxes is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31,
​ |  | 2022 |  | 2021
Loss from operations of reportable segements | ​ | $ | (217,084) | ​ | $ | (2,156,165)
General corporate expenses (b) | ​ |  | (1,001,894) | ​ |  | (2,550,412)
Interest income, net | ​ |  | 3,686 | ​ |  | 273
Unrealized loss on change in fair value of warrants classified as a liability | ​ |  | (2,637,800) | ​ |  | —
Other income (expense), net | ​ |  | 8,846 | ​ |  | (14,607)
Consolidated loss before provision for income taxes | ​ | $ | (3,844,246) | ​ | $ | (4,720,911)
​
| (a) | Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.
| (b) | General corporate expenses consists of Selling, general and administrative expenses that are not specifically identifiable to a segment.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration